Answers are grounded in this paper and cite their sources.
First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.
No takes yet. Share an insight, caveat, or question.
Gadgeel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: